21-Sep-2021 - Johann Wolfgang Goethe-Universität Frankfurt (Main)

The Paul Ehrlich and Ludwig Darmstaedter Prize 2022 will be awarded to Katalin Karikó, Özlem Türeci and Uğur Şahin

The three award winners are being honoured for their achievements in the development of mRNA for preventive and therapeutic purposes

Katalin Karikó, Özlem Türeci, and Uğur Şahin have established a technology platform that is likely to initiate a paradigm shift in some areas of medicine - away from the external application of immunising antigens or therapeutically effective proteins to their internal production within the cells of patients. The spectacularly rapid development of a highly effective vaccine against the coronavirus disease COVID-19, which has proven to play a decisive role in the worldwide containment of the SARS-CoV2 pandemic, has been an outstanding success.

mRNAs are messenger molecules that carry genetic information from the DNA in the cell nucleus to the ribosomes in the cytoplasm, where they instruct protein synthesis. In this way, genetic information is translated into biological function. In contrast to DNA, mRNAs are very unstable molecules and insufficient protein production has been considered their main weakness. In addition, our immune system normally regards externally applied mRNA as an unwanted intruder and in response releases inflammatory signal molecules. This signal cascade serves to eventually inhibit the translation of the externally derived mRNA. While great (and to date largely unfulfilled) hopes were placed in gene therapies with DNA, mRNA seemed to have little to offer for medical purposes.

Undeterred by the dominance of DNA research in the 1990s, however, Katalin Karikó remained true to her goal of stimulating the production of proteins by introducing mRNA into living cells, in order to provide missing or replace faulty proteins in patients suffering from hereditary disorders, such as cystic fibrosis. She was convinced of the potential of such protein replacement therapies. Unlike DNA therapeutics, mRNA does not have to enter the cell´s nucleus to exert its effect. Unlike DNA therapeutics, which carry a risk of mutagenicity, RNA does not integrate into the genome of its target cell; moreover, because it is rapidly degraded, its temporal effects can be well controlled. Despite many obstacles, Karikó, who conducts research at the University of Pennsylvania, finally achieved a decisive breakthrough: she discovered how to blunt the body's own defence response against synthetic mRNA, and consequently, how to significantly increase intracellular protein production.

Uğur Şahin and Özlem Türeci have a background in cancer research. Working at the medical schools of Homburg/Saar and Mainz since the mid-1990s, they have focused on developing cancer vaccines, including truly individualized ones, to present a patient's immune system with the antigens of his or her own tumour to stimulate target-specific destruction. In the late 1990s, they began a systematic discovery process to solve the basic mRNA-associated problem of short-lived protein production. They developed a series of optimized designs for various structural components of mRNA, thereby significantly increasing both its intracellular stability and its translational efficiency. In 2006, the results of this work won them the first Go.Bio award of the Federal Ministry of Education and Research, which motivated them to found BioNTech in 2008.

In the years to follow, they further improved vaccine efficacy by strategies to deliver RNA into dendritic cells (DCs) located in lymphoid tissues. This particular DC species are the "high-performance trainers" of the immune system. With a lipid nanoparticle formulation, the two doctors and their team achieved body-wide targetting of mRNA into DCs, thereby generating a large number of immune cells that precisely recognized only the cancer cells. These breakthrough improvements formed the basis for the successful use of mRNA for various human applications. To successfully realize their original vision of an individualized vaccine technology, Uğur Şahin and Özlem Türeci developed a breakthrough approach in which each mRNA vaccine is tailored according to the genetic profile of the patient´s tumor that can be universally applied to different types of cancer.

During the last years, BioNTech has made significant progress in the clinical application of cancer vaccines. Several of the company’s cancer vaccines have successfully passed the first phase of clinical trials. The principle of targeting DCs in lymphoid tissues and the knowledge and knowhow gained in the development of cancer vaccines later decisively contributed to the rapid availability of the COVID19 mRNA vaccine. Moreover, BioNTech's COVID19 vaccine greatly benefited from the incorporation of the optimized designs for various structural components of mRNAs originally developed by Uğur Şahin and Özlem Türeci for their cancer vaccines.

Katalin Karikó joined BioNTech in 2013. The non-immunogenic mRNA modifications she discovered are essential for the development of protein replacement therapies. They are not essential for the development of cancer vaccines, where cellular immunity is most important. After all, a certain immune stimulation (an adjuvant effect) is mandatory for every successful vaccination. Non-immunogenic mRNA, however, offers substantial advantages in case of infectious disease vaccines, where humoral immunity is the main goal. With immunogenic mRNA it would have been much more difficult to develop a highly effective COVID-19 vaccine in a comparably short time. Thus, both mRNA vaccines that have been successful in the fight against the Corona pandemic to date incorporate Katalin Karikó's discovery of non-immunogenic mRNA alongside other optimized mRNA components. Their adjuvant effect is ensured by their lipid formulations.

The prizes will be awarded - together with the prizes of the year 2021 - on 14 March 2022 by the Chairman of the Scientific Council of the Paul Ehrlich Foundation in the Paulskirche in Frankfurt.

Facts, background information, dossiers

  • coronaviruses
  • Covid-19
  • SARS-CoV-2
  • mRNA vaccines
  • messenger RNA
  • protein synthesis
  • protein replacement…
  • cancer vaccines

More about Uni Frankfurt am Main

  • News

    New substance classes for nanomaterials

    Chemists at Goethe University Frankfurt have developed two new classes of materials in the field of nanomaterials and investigated them together with their cooperation partners at the University of Bonn: for the first time, they have succeeded in producing a nano sphere of silicon atoms and ... more

    SARS-CoV-2: Achilles’ heel of viral RNA

    Certain regions of the SARS-CoV-2 genome might be a suitable target for future drugs. This is what researchers at Goethe University, together with their collaborators in the international COVID-19-NMR consortium, have now discovered. With the help of dedicated substance libraries, they have ... more

    Pharmaceutical research: when active substance and target protein “embrace” each other

    Scientists at Goethe University Frankfurt, together with colleagues from Darmstadt, Heidelberg, Oxford and Dundee (UK), have investigated how the fit of potent inhibitors to their binding sites can be optimised so that they engage longer with their target proteins. Long target residency has ... more

  • q&more articles

    From feast to famine and back – no problem for bacteria

    Bacteria are true survivors. In the course of evolution, they have developed numerous strategies to adapt to rapidly changing, uncertain environmental conditions. Their metabolism is much more sophisticated than that of human beings. Within minutes they can regulate their gene expression an ... more

    Why biosimilars and not biogenerics?

    Medicines produced using genetic techniques have existed since 2006, called “similar biological medicinal products” or “biosimilars”. Until a year ago, this was a fairly low-profile group, even in expert circles. This has all changed now, however, with the recent licensing of the first bios ... more

    Paradigm shift

    What would medicine be without drugs? But are these drugs being used optimally today? Not at all, as we now know thanks to the findings of molecular medicine. Because for the use of these drugs, it is important to observe two aspects: the disease and the patient. Only slowly is it becom ... more

  • Authors

    Prof. Dr. Jörg Soppa

    Jörg Soppa, born in 1958, studied biochemistry in Tübingen and then went on to do his doctorate at the Max Planck Institute of Biochemistry in Martinsried near Munich. In 1990 he established his own research group there and held courses at the Institute of Genetics and Microbiology of Munic ... more

    Prof. Dr. Heinfried H. Radeke

    Heinfried H. Radeke studied medicine at the Hannover Medical School (MHH) and received his medical license in 1985. His Ph.D. thesis was recognized as the best research dissertation of 1986. After two years as an assistant physician at the Göttingen University Hospital, he began his career ... more

    Prof. Dr. Theo Dingermann

    Theodor Dingermann, born 1948, studied pharmacy in Erlangen ­and received his doctor title in 1980 to become Dr. rer. nat. In 1990 he was offered the C4 professorship at the Institute for Pharmaceutical Biology, University of Frankfurt.  From 2000 to 2004 he was President of the German Phar ... more

More about BioNTech

q&more – the networking platform for quality excellence in lab and process

The q&more concept is to increase the visibility of recent research and innovative solutions, and support the exchange of knowledge. In the broad spectrum of subjects covered, the focus is on achieving maximum quality in highly innovative sectors. As a modern knowledge platform, q&more offers market participants one-of-a-kind networking opportunities. Cutting-edge research is presented by authors of international repute. Attractively presented in a high-quality context, and published in German and English, the original articles introduce new concepts and highlight unconventional solution strategies.

> more about q&more

q&more is supported by: